Short Communication: No Significant Changes in Weight and Body Fat Mass in Suppressed HIV-Infected Patients Switched to Dual Combination Lamivudine Plus Dolutegravir or Raltegravir

Calza, Leonardo; Borderi, Marco; Colangeli, Vincenzo; Testi, Diletta; Amedeo, Alberto; Bon, Isabella; Re, Maria Carla; Viale, Pierluigi

doi:10.1089/aid.2020.0117

Cited by 7 publications

(5 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three studies (all in virologically suppressed PWH) examined the effect of dolutegravir plus lamivudine on BMD (Table S4 in Supplementary Material) [ 71 – 73 ]. Two of these studies reported significant improvements from baseline in spine BMD at Week 48 (mean increase from baseline in lumbar spine BMD, + 0.03 g/cm 2 ; P = 0.001) [ 71 ] or Week 96 (percentage increase from baseline in spine BMD, 3.2; P < 0.001) [ 72 ], and the third reported no difference compared with baseline [ 73 ].…”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

“…Three studies (all in virologically suppressed PWH) examined the effect of dolutegravir plus lamivudine on BMD (Table S4 in Supplementary Material) [71][72][73]. Two of these studies reported significant improvements from baseline in spine BMD at Week 48 (mean increase from baseline in lumbar spine BMD, ?…”

Section: Bone Healthmentioning

confidence: 99%

See 2 more Smart Citations

HIV Treatment with the Two-Drug Regimen Dolutegravir Plus Lamivudine in Real-world Clinical Practice: A Systematic Literature Review

Patel

Evitt

Mariolis³

et al. 2021

Infect Dis Ther

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

HIV Treatment with the Two-Drug Regimen Dolutegravir Plus Lamivudine in Real-world Clinical Practice: A Systematic Literature Review

Patel

Evitt

Mariolis³

et al. 2021

Infect Dis Ther

View full text Add to dashboard Cite

show abstract

“…Data on weight gain associated with 2DRs are limited; however, our findings are consistent with what has been reported. Median weight gain at week 48 reported for DTG/3TC ranged between 0.8 and 4.5 kg [32,[42][43][44], whereas-for DTG/RPV-one study reported a median weight gain at week 48 of 1.8 kg [45] and another study reported a gain of 1.4 kg [46]. These differences may reflect the heterogeneity of the populations studied, including treatment status (treatment naïve or experienced) and the number of regimens and duration of treatment prior to inclusion.…”

Section: Discussionmentioning

confidence: 99%

Efficacy, durability, and tolerability of dolutegravir/lamivudine and dolutegravir/rilpivirine for the treatment of HIV in a real‐world setting in Belgium

et al. 2022

View full text Add to dashboard Cite

Objectives A paradigm shift from three‐drug regimens to two‐drug regimens (2DRs) is currently taking place in real‐world clinical practice. This study aimed to describe the efficacy, durability, and tolerability of dolutegravir (DTG)/lamivudine (3TC) and DTG/rilpivirine (RPV) in a real‐world setting. Methods This was a retrospective, observational, multicentre (ten centres in Belgium) study involving adult treatment‐naïve and treatment‐experienced people living with HIV on DTG/3TC or DTG/RPV between 1 January 2019 and 30 September 2020. The primary endpoint was rate of virological suppression (VS; plasma HIV‐1 viral load [VL] <50 copies/ml) using an on‐treatment analysis. Main secondary endpoints included the proportion of people that experienced loss of VS (LVS; defined as two consecutive HIV‐1 VLs of >200 copies/ml after initially achieving VS) and a resistance analysis at the time of LVS; rate, incidence, and reasons for discontinuation of treatment (stopping treatment or changing any component of the 2DR); and change in weight, along with the proportion of people reporting a >10% weight gain. Ordinal logistic regression analysis examined associations between baseline variables and >10% on‐treatment weight gain. Results Overall, 948 people were included, of whom 734 (77%) were on DTG/3TC and 214 (23%) were on DTG/RPV. Baseline characteristics included 54% aged ≥50 years, 31% female, 31% Black sub‐Saharan African, 95% treatment‐experienced, and 8% with HIV‐1 VL ≥50 copies/ml. Through 48 weeks, the rate of VS for the overall cohort was 98.3% (99.1% with 3TC; 96.2% with RPV). LVS was observed in 0.5% (n = 5) of the overall population (n = 1 [3TC group], n = 4 [RPV group]). There were 40 treatment discontinuations (4.2%, n = 27 [3TC group]; n = 13 [RPV group]), corresponding to an incidence of 4.7 per 100 patient‐years. The most common reason for discontinuation was an adverse event (1.4%), with neurotoxicity the most frequent (0.5%). Median on‐treatment weight gain at week 48 was 1 kg (interquartile range [IQR] −1–3) overall, 1 kg (IQR −1–3) in the 3TC group, and 2 kg (IQR 0–4) in the RPV group. A >10% weight increase was observed in 6.3% of people. Regression analysis showed that being on a tenofovir disoproxil fumarate‐based regimen prior to 2DR initiation was the only variable associated with a >10% increase in weight from baseline (odds ratio 3.48; 95% confidence interval 1.13–10.68; p = 0.038). Conclusion In this real‐world analysis, the 2DRs analysed were effective, durable, and safe for those who were treatment‐naive and treatment‐experienced. A slight increase in weight was associated with these regimens.

show abstract

“…However, these same effects have not been observed by other researchers in similar studies. [11][12][13] Regarding pregnancy, increased antepartum and postpartum weekly weight gain was reported for dolutegravir compared with efavirenz in an African population but still below the average weight gain of women not living with HIV. 14,15 Gestational weight gain is a potentially modifiable risk factor for immediate adverse pregnancy outcomes and has long-term implications.…”

Section: Introductionmentioning

confidence: 99%

Effects of Initiating Raltegravir-Based Versus Efavirenz-Based Antiretroviral Regimens During Pregnancy on Weight Changes and Perinatal Outcomes: NICHD P1081

Coutinho

Warshaw

Duarte

et al. 2022

JAIDS Journal of Acquired Immune Deficiency Syndromes

View full text Add to dashboard Cite

Background: Integrase inhibitors have been associated with excess gestational weight gain that may lead to adverse pregnancy outcomes (APOs). This post hoc analysis of NICHD P1081 compared antepartum changes in weight and body mass index (BMI) in pregnant women initiating raltegravir-or efavirenz-based combined antiretroviral therapy (cART) and examined associations between rates of weight gain and APOs.

show abstract

Short Communication: No Significant Changes in Weight and Body Fat Mass in Suppressed HIV-Infected Patients Switched to Dual Combination Lamivudine Plus Dolutegravir or Raltegravir

Cited by 7 publications

References 11 publications

HIV Treatment with the Two-Drug Regimen Dolutegravir Plus Lamivudine in Real-world Clinical Practice: A Systematic Literature Review

HIV Treatment with the Two-Drug Regimen Dolutegravir Plus Lamivudine in Real-world Clinical Practice: A Systematic Literature Review

Efficacy, durability, and tolerability of dolutegravir/lamivudine and dolutegravir/rilpivirine for the treatment of HIV in a real‐world setting in Belgium

Effects of Initiating Raltegravir-Based Versus Efavirenz-Based Antiretroviral Regimens During Pregnancy on Weight Changes and Perinatal Outcomes: NICHD P1081

Contact Info

Product

Resources

About